Physical property of troglitazone, an equal mixture of four stereoisomers

International Journal of Pharmaceutics

Volumn 248, Issue 1-2, 2002, Pages 71-80

  Suzuki, Nobuyuki ^a   Kasahara, Ko ^a   Hasegawa, Hirokazu ^a   Kawasaki, Takao ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Conglomerate; Diastereomer; Hydration; Solid state stability; Solubility; Troglitazone

Indexed keywords

ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

ARTICLE; CHIRALITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HYDRATION; NONPHOTOCHEMICAL QUENCHING; POWDER; PRIORITY JOURNAL; SOLID STATE; STEREOISOMERISM; THERMOSTABILITY; WATER ABSORPTION; X RAY DIFFRACTION;

CHEMISTRY, PHARMACEUTICAL; CHROMANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMIDITY; SOLUBILITY; STEREOISOMERISM; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0037032465     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00430-1     Document Type: Article

References (19)

1. Ahlneck C., Zografi G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int. J. Pharm. 62:1990;87-95.
2. Bartolomei M., Bertocchi P., Cotta Ramusino M., Santucci N., Valvo L. Physicochemical characterization of the modifications I and II of (R,S) propranolol hydrochloride: solubility and dissolution studies. J. Pharm. Biomed. Anal. 21:1999;299-309.
3. Bauer J., Spanton S., Henry R., Quick J., Dziki W., Porter W., Morris J. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 18:2001;859-866.
4. Brittain H.G. Crystallographic consequences of molecular dissymmetry. Pharm. Res. 7:1990;683-690.
5. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1988;1549-1558.
6. Grant D.J.W., Brittain H.G. Solubility of pharmaceutical solids. Brittain H.G., Physical Characterization of Pharmaceutical Solids. 1995;380-381 Marcel Dekker, New York.
7. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17:2000;397-404.
8. Horikoshi H., Yoshioka T., Kawasaki T., Nakamura K., Matsunuma N., Yamaguchi K., Sasahara K. Troglitazone (CS-045), a new antidiabetic drug. Annu. Rep. Sankyo Res. Lab. 46:1994;1-57.
9. Khankari R., Chen L., Grant D.J.W. Physical characterization of nedocromil sodium hydrates. J. Pharm. Sci. 87:1998;1052-1061.
10. Kobayashi K., Fukuhara H., Hata T. Crystal and molecular structure of (±)-(5R*)-[4-(6-Hydroxy-(2R*)-2,5,7,8-tetramethylchroman- 2-ylmethoxy)benzyl]-2,4-dioxothiazollidine monohydrate. Anal. Sci. 16:2000;443-444.
11. Kobayashi Y., Ito S., Itai S., Yamamoto K. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 193:2000;137-146.
12. McCauley J.A., Brittain H.G. Thermal methods of analysis. Brittain H.G., Physical Characterization of Pharmaceutical Solids. 1995;223-251 Marcel Dekker, New York.
13. Rustichelli C., Gamberini G., Ferioli V., Gamberini M.C., Ficarra R., Tommasini S. Solid-state study of polymorphic drugs: carbamazepine. J. Pharm. Biomed. Anal. 23:2000;41-54.
14. Stokes R.H. Standard solutions for humidity control at 25 °C. Ind. Eng. Chem. 41:1949;2013.
15. Suter S., Nolan J., Wallace P., Gumbiner B., Olefsky J. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-203.
16. Suzuki, N., Takemura, A., Miyamoto, A., Yoshioka, T., Tsutsumi, S., Kawasaki, T., 2002. Direct chiral separation of troglitazone stereoisomers using reversed-phase high-performance liquid chromatography. J. Pharm. Biomed. Anal. 30, 381-394.
17. Yoshioka T., Aizawa Y., Fujita T., Nakamura K., Sasahara K., Kuwano H., Kinoshita T., Horikoshi H. Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045. Chem. Pharm. Bull. 39:1991;2124-2125.
18. Yoshioka T., Fujita T., Kanai T., Aizawa Y., Kurumada T., Hasegawa K., Horikoshi H. Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem. 32:1989;421-428.
19. Zografi G. States of water associated with solids. Drug Dev. Ind. Pharm. 14:1988;1905-1926.